Oncodesign Precision Medicine

Oncodesign Precision Medicine (OPM) is a biopharmaceutical company focused on developing therapies for resistant and metastatic cancers. The company originated as a spin-off from Oncodesign SA, which was founded in 1995 in Dijon, France, by Philippe Genne. This strategic restructuring in 2022 separated the parent company's drug discovery service activities, which became Oncodesign Services, from its biotech and artificial intelligence arm, which now constitutes OPM. This move allowed OPM to operate independently, concentrating on precision medicine. Following the split, OPM was listed on the Euronext Access+ market in Paris in October 2022.

Philippe Genne, who holds a PhD in Pharmacology, transitioned from leading the original Oncodesign SA to become the Chairman and CEO of OPM. His extensive background includes managing clinical development programs at Debiopharm and a long-standing entrepreneurial career in life sciences, which provides OPM with experienced leadership. The executive team also includes co-founders Karine Lignel (COO) and Jan Hoflack (CSO), who have worked together since 2008.

OPM's business model is centered on the discovery and development of therapeutic and diagnostic molecules, which it advances through partnerships and licensing agreements with pharmaceutical and biotechnology companies. Revenue is generated through milestone payments and future royalties from these collaborations. The company targets unmet medical needs in oncology and also explores applications in other areas, such as neurodegenerative diseases. A significant partnership includes a collaboration with Servier to identify new therapeutic targets in pancreatic cancer.

The company's core offering relies on three proprietary technology platforms. The first, OncoSNIPER, uses artificial intelligence and machine learning to analyze clinical data and identify novel therapeutic targets, aiming to overcome treatment resistance. Nanocyclix® is a platform for designing and selecting potent and selective small macrocyclic kinase inhibitors, which form the basis of its drug discovery pipeline. The third platform, PROMETHE®, is dedicated to developing radiolabeled molecules for systemic radiotherapy, a form of targeted cancer treatment. OPM's lead asset, OPM-101, a RIPK2 inhibitor developed via the Nanocyclix platform, has completed Phase I trials and is advancing to further clinical studies for treating advanced melanoma.

Keywords: Oncodesign Precision Medicine, biopharmaceutical, precision medicine, oncology, metastatic cancer, drug discovery, therapeutic solutions, diagnostic solutions, Philippe Genne, OncoSNIPER, artificial intelligence, Nanocyclix, kinase inhibitors, PROMETHE, systemic radiotherapy, OPM-101, RIPK2 inhibitor, LRRK2, drug development, Euronext Growth, cancer research, targeted therapy, clinical trials, radiotheranostics, biomarkers